Penetrating Crohn’s Disease and Fistulae

  • Nicola S. FearnheadEmail author


Crohn’s disease can affect the bowel anywhere in the gastrointestinal tract, but most commonly affects the small bowel and perianal areas, where it may cause fistulae to form. Both enteric fistulae arising from the small bowel and perianal fistulae affecting the anorectum cause significant suffering for patients and are clinically difficult to treat. This chapter covers the manifestations and management options for fistulating Crohn’s disease.


Crohn’s disease Perianal fistula Enteric fistula Enterocutaneous fistula 


  1. Bellolio F, Cohen Z, Macrae HM, O'connor BI, Huang H, Victor JC, Mcleod RS (2013) Outcomes following surgery for perforating Crohn’s disease. Br J Surg 100:1344–1348CrossRefGoogle Scholar
  2. Bor R, Farkas K, Balint A, Szucs M, Abraham S, Baradnay G, Wittmann T, Szepes Z, Nagy F, Molnar T (2015) Efficacy of combined anti-TNF-alpha and surgical therapy in perianal and enterocutaneous fistulizing Crohn's disease—clinical observations from a tertiary eastern European center. Scand J Gastroenterol 50:182–187CrossRefGoogle Scholar
  3. Bor R, Farkas K, Fabian A, Balint A, Milassin A, Rutka M, Matuz M, Nagy F, Szepes Z, Molnar T (2017) Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease. PLoS One 12:e0172916CrossRefGoogle Scholar
  4. Borley NR, Mortensen NJ, Jewell DP (1999) MRI scanning in perianal Crohn's disease: an important diagnostic adjunct. Inflamm Bowel Dis 5:231–233 discussion 234CrossRefGoogle Scholar
  5. Brochard C, Siproudhis L, Leveque J, Grouin A, Mallet AL, Bretagne JF, Ropert A, Bouguen G (2017) Factors associated with fecal incontinence in women of childbearing age with Crohn’s disease. Inflamm Bowel Dis 23:775–780CrossRefGoogle Scholar
  6. Coelho R, Magro F, Silva M, Macedo G (2016) Early surgery in Crohn's disease patients with entero-urinary fistulas: does it change the prognosis? Scand J Gastroenterol 51:679–683CrossRefGoogle Scholar
  7. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132:52–65CrossRefGoogle Scholar
  8. de Groof EJ, Sahami S, Lucas C, Ponsioen CY, Bemelman WA, Buskens CJ (2016) Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment. Color Dis 18:667–675CrossRefGoogle Scholar
  9. El-Gazzaz G, Hull T, Church JM (2012) Biological immunomodulators improve the healing rate in surgically treated perianal Crohn's fistulas. Color Dis 14:1217–1223CrossRefGoogle Scholar
  10. Farrer K, Lal S, Teubner A, Harper L, Abraham A, Myers A, Carlson GL (2015) Fistuloclysis and distal enteral feeding in acute intestinal failure. Clin Nutr ESPEN 10:e189CrossRefGoogle Scholar
  11. Gecse K, Khanna R, Stoker J, Jenkins JT, Gabe S, Hahnloser D, D'Haens G (2013) Fistulizing Crohn's disease: diagnosis and management. United European Gastroenterol J 1:206–213CrossRefGoogle Scholar
  12. Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, Panes J, van Assche G, Liu Z, Hart A, Levesque BG, D'Haens G, World Gastroenterology Organization, International Organisation for Inflammatory Bowel Diseases IOIBD, European Society of Coloproctology and Robarts Clinical Trials (2014) A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut 63:1381–1392CrossRefGoogle Scholar
  13. Geltzeiler CB, Hart KD, Lu KC, Deveney KE, Herzig DO, Tsikitis VL (2015) Trends in the surgical Management of Crohn's disease. J Gastrointest Surg 19:1862–1868CrossRefGoogle Scholar
  14. Gligorijevic V, Spasic N, Bojic D, Protic M, Svorcan P, Maksimovic B, Markovic V, Krivokapic Z, Jojic N (2010) The role of pelvic MRI in assesment of combined surgical and infliximab treatment for perianal Crohn's disease. Acta Chir Iugosl 57:89–95CrossRefGoogle Scholar
  15. Goel RM, Blaker P, Mentzer A, Fong SC, Marinaki AM, Sanderson JD (2015) Optimizing the use of thiopurines in inflammatory bowel disease. Ther Adv Chronic Dis 6:138–146CrossRefGoogle Scholar
  16. Gottgens KW, Jeuring SF, Sturkenboom R, Romberg-Camps MJ, Oostenbrug LE, Jonkers DM, Stassen LP, Masclee AA, Pierik MJ, Breukink SO (2017) Time trends in the epidemiology and outcome of perianal fistulizing Crohn's disease in a population-based cohort. Eur J Gastroenterol Hepatol 29:595–601CrossRefGoogle Scholar
  17. Greveson K, Woodward S (2013) Exploring the role of the inflammatory bowel disease nurse specialist. Br J Nurs 22:952–954 956–958CrossRefGoogle Scholar
  18. Hart AL, Lomer M, Verjee A, Kemp K, Faiz O, Daly A, Solomon J, Mclaughlin J (2017) What are the top 10 research questions in the treatment of inflammatory bowel disease? A priority setting partnership with the James Lind Alliance. J Crohns Colitis 11:204–211CrossRefGoogle Scholar
  19. Hernandez-Sampelayo P, Seoane M, Oltra L, Marin L, Torrejon A, Vera MI, Garcia V, Lazaro P, Parody E, Blasco AJ, Casellas F (2010) Contribution of nurses to the quality of care in management of inflammatory bowel disease: a synthesis of the evidence. J Crohns Colitis 4:611–622CrossRefGoogle Scholar
  20. Hvas CL, Dahlerup JF, Jacobsen BA, Ljungmann K, Qvist N, Staun M, Tottrup A (2011) Diagnosis and treatment of fistulising Crohn’s disease. Dan Med Bull 58:C4338PubMedGoogle Scholar
  21. Irvine EJ, McMaster IBD Study Group (1995) Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. J Clin Gastroenterol 20:27–32CrossRefGoogle Scholar
  22. Kariyawasam VC, Ward MG, Blaker PA, Patel KV, Goel R, Sanderson JD, Irving PM (2017) Thiopurines dosed to a therapeutic 6-thioguanine level in combination with adalimumab are more effective than subtherapeutic thiopurine-based combination therapy or adalimumab monotherapy during induction and maintenance in patients with long-standing Crohn's disease. Inflamm Bowel Dis 23:1555–1565CrossRefGoogle Scholar
  23. Karmiris K, Bielen D, Vanbeckevoort D, Vermeire S, Coremans G, Rutgeerts P, Van Assche G (2011) Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 9:130–136CrossRefGoogle Scholar
  24. Kasparek MS, Glatzle J, Temeltcheva T, Mueller MH, Koenigsrainer A, Kreis ME (2007) Long-term quality of life in patients with Crohn's disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum 50:2067–2074CrossRefGoogle Scholar
  25. Keshaw H, Foong KS, Forbes A, Day RM (2010) Perianal fistulae in Crohn's disease: current and future approaches to treatment. Inflamm Bowel Dis 16:870–880CrossRefGoogle Scholar
  26. Kosmidis C, Anthimidis G (2011) Emergency and elective surgery for small bowel Crohn's disease. Tech Coloproctol 15(Suppl 1):S1–S4CrossRefGoogle Scholar
  27. Lee MJ, Heywood N, Sagar PM, Brown SR, Fearnhead NS, ACPGBI Perianal Crohn's Disease Group (2017a) Association of Coloproctology of Great Britain and Ireland consensus exercise on surgical management of fistulating perianal Crohn's disease. Color Dis 19:418–429CrossRefGoogle Scholar
  28. Lee MJ, Heywood N, Sagar PM, Brown SR, Fearnhead NS, pCD Collaborators (2017b) Surgical management of fistulating perianal Crohn's disease: a UK survey. Color Dis 19:266–273CrossRefGoogle Scholar
  29. Lloyd DA, Gabe SM, Windsor AC (2006) Nutrition and management of enterocutaneous fistula. Br J Surg 93:1045–1055CrossRefGoogle Scholar
  30. Manne A, Ahmed MB, Malik TA (2016) Predictors of outcome of Rectovaginal fistula surgery in women with Crohn's disease. J Clin Med Res 8:126–129CrossRefGoogle Scholar
  31. Mcnair AG, Heywood N, Tiernan J, Verjee A, Bach SP, Fearnhead NS, ORACLE Collaboration (2017) A national patient and public colorectal research agenda: integration of consumer perspectives in bowel disease through early consultation. Color Dis 19:O75–O85CrossRefGoogle Scholar
  32. Milito G, Lisi G, Venditti D, Campanelli M, Aronadio E, Grande M (2017) Surgical treatment of rectovaginal fistula in Crohn's disease: a tertiary center experience. Surg Technol Int 30:113–116PubMedGoogle Scholar
  33. Molendijk I, Peeters KC, Baeten CI, Veenendaal RA, Van Der Meulen-De Jong AE (2014) Improving the outcome of fistulising Crohn's disease. Best Pract Res Clin Gastroenterol 28:505–518CrossRefGoogle Scholar
  34. Morar P, Read J, Arora S, Hart A, Warusavitarne J, Green J, Sevdalis N, Edwards C, Faiz O (2015) Defining the optimal design of the inflammatory bowel disease multidisciplinary team: results from a multicentre qualitative expert-based study. Frontline Gastroenterol 6:290–297CrossRefGoogle Scholar
  35. Mullen R, Deveraj S, Suttie SA, Matthews AG, Yalamarthi S (2011) MR imaging of fistula in ano: indications and contribution to surgical assessment. Acta Chir Belg 111:393–397CrossRefGoogle Scholar
  36. Nanda KS, Cheifetz AS, Moss AC (2013) Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 108:40–47 quiz 48CrossRefGoogle Scholar
  37. Nasseri Y, Cassella L, Berns M, Zaghiyan K, Cohen J (2016) The anal fistula plug in Crohn's disease patients with fistula-in-ano: a systematic review. Color Dis 18:351–356CrossRefGoogle Scholar
  38. Nielsen OH, Rogler G, Hahnloser D, Thomsen OO (2009) Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 6:92–106CrossRefGoogle Scholar
  39. Nunes J, Santos PM, Tavares L (2010) Complete resolution of enterocolic fistulas with infliximab. BioDrugs 24(Suppl 1):28–30CrossRefGoogle Scholar
  40. Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S, Collaborators ACSG (2016) Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 388:1281–1290CrossRefGoogle Scholar
  41. Panes J, Rimola J (2017) Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol 14(11):652CrossRefGoogle Scholar
  42. Parks AG, Gordon PH, Hardcastle JD (1976) A classification of fistula-in-ano. Br J Surg 63:1–12CrossRefGoogle Scholar
  43. Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123:132–142CrossRefGoogle Scholar
  44. Poritz LS, Gagliano GA, Mcleod RS, Macrae H, Cohen Z (2004) Surgical management of entero and colocutaneous fistulae in Crohn's disease: 17 year's experience. Int J Color Dis 19:481–485 discussion 486CrossRefGoogle Scholar
  45. Poritz LS, Rowe WA, Koltun WA (2002) Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 45:771–775CrossRefGoogle Scholar
  46. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, Podolsky DK, Sands BE, Braakman T, Dewoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398–1405CrossRefGoogle Scholar
  47. Sampietro GM, Casiraghi S, Foschi D (2013) Perforating Crohn's disease: conservative and surgical treatment. Dig Dis 31:218–221CrossRefGoogle Scholar
  48. Sanchez-Guillen L, Lopez De Los Reyes R, Vives-Rodriguez E, Mato Iglesias A, Canton-Blanco A (2016) Enteral nutrition in Crohn's disease with a high output enteroatmospheric fistula. Cir Esp 94:547–550CrossRefGoogle Scholar
  49. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice Committee (2003) AGA technical review on perianal Crohn's disease. Gastroenterology 125:1508–1530CrossRefGoogle Scholar
  50. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350:876–885CrossRefGoogle Scholar
  51. Sauk J, Nguyen D, Yajnik V, Khalili H, Konijeti G, Hodin R, Bordeianou L, Shellito P, Sylla P, Korzenik J, Friedman S, Ananthakrishnan AN (2014) Natural history of perianal Crohn's disease after fecal diversion. Inflamm Bowel Dis 20:2260–2265CrossRefGoogle Scholar
  52. Schreiber S, Lawrance IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ (2011) Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 33:185–193CrossRefGoogle Scholar
  53. Schwartz DA, Ghazi LJ, Regueiro M, Fichera A, Zoccali M, ONG EM, Mortele KJ, Crohn's & Colitis Foundation of America, Inc. (2015) Guidelines for the multidisciplinary management of Crohn's perianal fistulas: summary statement. Inflamm Bowel Dis 21:723–730CrossRefGoogle Scholar
  54. Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ (2002) The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 122:875–880CrossRefGoogle Scholar
  55. Siegmund B, Feakins RM, Barmias G, Ludvig JC, Teixeira FV, Rogler G, Scharl M (2016) Results of the fifth scientific workshop of the ECCO (II): pathophysiology of perianal Fistulizing disease. J Crohns Colitis 10:377–386CrossRefGoogle Scholar
  56. Singh B, Mortensen NJM, Jewell DP, George B (2004) Perianal Crohn's disease. Br J Surg 91:801–814CrossRefGoogle Scholar
  57. Solomon MJ (1996) Fistulae and abscesses in symptomatic perianal Crohn's disease. Int J Color Dis 11:222–226CrossRefGoogle Scholar
  58. Stidham RW, Cross RK (2016) Endoscopy and cross-sectional imaging for assessing Crohns disease activity. Tech Gastrointest Endosc 18:123–130CrossRefGoogle Scholar
  59. Thomassin L, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, Savoye-Collet C (2017) Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease. World J Gastroenterol 23:4285–4292CrossRefGoogle Scholar
  60. Thompson MJ, Epanomeritakis E (2008) An accountable fistula management treatment plan. Br J Nurs 17:438–440CrossRefGoogle Scholar
  61. Tiernan J, Cook A, Geh I, George B, Magill L, Northover J, Verjee A, Wheeler J, Fearnhead N (2014) Use of a modified Delphi approach to develop research priorities for the association of coloproctology of Great Britain and Ireland. Color Dis 16:965–970CrossRefGoogle Scholar
  62. Tozer P, Borowski DW, Gupta A, Yassin N, Phillips R, Hart A (2015) Managing perianal Crohn's fistula in the anti-TNFalpha era. Tech Coloproctol 19:673–678CrossRefGoogle Scholar
  63. Tozer PJ, Burling D, Gupta A, Phillips RK, Hart AL (2011) Review article: medical, surgical and radiological management of perianal Crohn's fistulas. Aliment Pharmacol Ther 33:5–22CrossRefGoogle Scholar
  64. Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D'hoore A, Penninckx F, Marchal G, Cornillie F, Rutgeerts P (2003) Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 98:332–339CrossRefGoogle Scholar
  65. Yassin NA, Askari A, Warusavitarne J, Faiz OD, Athanasiou T, Phillips RK, Hart AL (2014) Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn's disease. Aliment Pharmacol Ther 40:741–749CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Cambridge University Hospitals NHS Foundation TrustCambridgeUK

Personalised recommendations